Enzalutamide in metastatic prostate cancer before chemotherapy. - Wikidata - wikimedia - TriplyDB

Enzalutamide in metastatic prostate cancer before chemotherapy.

Enzalutamide in metastatic prostate cancer before chemotherapy.

http://www.wikidata.org/entity/Q34422206

about

Immunobiology and immunotherapy in genitourinary malignancies Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer Galeterone for the treatment of advanced prostate cancer: the evidence to date Splice Variants of Androgen Receptor and Prostate Cancer Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer Clonal origin and spread of metastatic prostate cancer Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer Contemporary Management of Prostate Cancer Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science Enzalutamide Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer Sequence of treatment in locally advanced and metastatic renal cell carcinoma Mechanisms of resistance in castration-resistant prostate cancer (CRPC)Persistent androgen receptor addiction in castration-resistant prostate cancer Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy Targeting molecular resistance in castration-resistant prostate cancer ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies Urologic cancer in Japan: role of Japan at the frontier of issues in Asia Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer Targeting the androgen receptor in prostate and breast cancer: several new agents in development Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer Integrative clinical genomics of advanced prostate cancer.What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence Radioisotopes in management of metastatic prostate cancer Androgen deprivation therapy as backbone therapy in the management of prostate cancer Epigenetic modulators as therapeutic targets in prostate cancer A Urologist's Personal View of Prostate Cancer Targeting intratumoral androgens: statins and beyond Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide

P2860

Q26738668-CD6BCFB3-9B38-4E69-AFC4-10C7D87F0B10 Q26739708-6A8AE697-AEB4-4423-9605-6912E66DDBE1 Q26739887-006A6ED8-B39B-4905-A14F-397417DA9521 Q26740592-8A48D6D5-1EB6-46AC-A968-0EE2A5E54E53 Q26740601-97E058FF-83B1-47B7-8168-64481BC1B516 Q26744431-FCEF3DA1-9C1D-4440-A3C3-640800C1CD74 Q26746524-920A323C-1A6A-4688-AF71-335880EA7C5F Q26747699-01D581B6-88FD-4D87-82AA-8AEFD87A3AE6 Q26747782-F818C5D7-B8F2-4C0C-B20C-42F0675685F6 Q26748538-0EF746EA-FD16-42E0-9056-B3DBBEA83DE3 Q26750620-9F30C4DD-D043-42D0-96C3-E6B569057CC2 Q26752873-F7A950E9-D2AC-4A0F-9221-32E4664D1BF5 Q26766638-B8630435-F3D7-47EC-A95E-EA71B0FEBA60 Q26767456-28C0E408-1AC2-419A-8327-A59FE3625F15 Q26770428-26D33BA6-26D4-4C1B-B09A-ECE69A90054E Q26772883-F80D7D82-A884-46E7-834C-1F8853EC8A93 Q26773350-4287568D-AC31-43CA-A9FF-E69132F2E4B8 Q26773634-3201B2F9-495A-487D-8501-751CDB83D69D Q26773653-8374E178-BE43-4681-83D9-E62FCA029495 Q26774221-E703932A-9E70-4EA3-A5DE-146E6E702BB0 Q26777163-4C13347D-3509-4B40-A35E-A4AED5AE178D Q26777310-DA7F4F1A-8F4E-4030-AD6B-73F026B47756 Q26786543-A01310F7-1461-43E5-90E0-04A14B022ED2 Q26795445-668DA1D1-75E0-4118-8490-2C20D70371CA Q26796568-4BD2E188-A2D0-488F-BA08-3D2BE0CB4FD3 Q26796704-E1ADB1D8-8BE4-46CF-AE45-A72712F59D5E Q26798350-2E971A1E-2A91-4FB3-836A-1FD5DDAC61CF Q27002342-0C8D94F9-F63F-45A5-BAAD-C9F3FC9EC0E9 Q27009424-4368D2D8-95B0-41B7-97CC-141F31A7081D Q27011642-7EA9EFC5-C912-4E8C-A1A1-515B7500C531 Q27334558-F32AFCEF-8F89-4CDE-A456-69E93F7119B5 Q27853127-C18F51C1-9588-4B66-BEB4-FECAAE6A4190 Q27853170-5028F99B-B296-44A0-B9A1-9E1BCD45F26B Q28066240-328CBDEB-F69C-4901-9B19-1A551041E99C Q28068134-C40DCB1F-1E94-4E9D-A135-5124CF6F3E24 Q28071795-54919B42-0896-46AD-BD33-1A35DFECA34A Q28071912-7FF1A9E2-DE92-44DB-8BE1-B1E75E23F955 Q28072919-C383D936-2D11-45E1-A69A-D505D608229C Q28073619-B5C2223D-77C7-4E17-B2C1-761E4F26DFB6 Q28076820-C93695C1-C125-43CA-AB62-1FAFDACE98F8

P2860

Enzalutamide in metastatic prostate cancer before chemotherapy.

http://www.wikidata.org/entity/Q34422206

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Enzalutamide in metastatic prostate cancer before chemotherapy.

@ast

Enzalutamide in metastatic prostate cancer before chemotherapy.

@en

Enzalutamide in metastatic prostate cancer before chemotherapy.

@nl

type

label

Enzalutamide in metastatic prostate cancer before chemotherapy.

@ast

Enzalutamide in metastatic prostate cancer before chemotherapy.

@en

Enzalutamide in metastatic prostate cancer before chemotherapy.

@nl

prefLabel

Enzalutamide in metastatic prostate cancer before chemotherapy.

@ast

Enzalutamide in metastatic prostate cancer before chemotherapy.

@en

Enzalutamide in metastatic prostate cancer before chemotherapy.

@nl

P1433

Q34422206-CE2FCF22-9B7C-418E-A7F2-870A02775877

P1476

Q34422206-1C989B25-F39F-4FDE-A631-DED8582167D4

P2093

Q34422206-0406FF86-25B9-4D09-8BE4-D7F985359928

Q34422206-0E6ABE38-42C7-4550-A7BC-F629BB302EDF

Q34422206-1B4F2403-7AA0-47AF-8CF8-06F396823D94

Q34422206-2A112B0D-AB7B-4D47-9919-C9DF9C9B5237

Q34422206-3E0E0FAC-983F-4C0A-B932-2AB937DFA291

Q34422206-42C8335B-A314-4F88-8C82-3BE87219DC91

Q34422206-45DA5E31-48F6-4006-B0BE-A866E2542175

Q34422206-4F6146E1-0B7E-4518-89BC-0B7398F6E003

Q34422206-69B322BB-AFEF-422E-85EC-6D9A6A100851

Q34422206-6ACC2529-44FA-49FA-B77A-F6B4457DCCA5

P2860

Q34422206-08872D9A-346A-4BC4-B717-5391736A1C6B

Q34422206-2AB6E570-7E46-4410-8773-A6CB83A02079

Q34422206-485C924C-CB71-4B07-BC69-895E8BD01E53

Q34422206-4C190E6D-BF91-4273-B3B2-F89E5E778177

Q34422206-5A692D25-F316-4700-96E5-2B4E4314AB99

Q34422206-5CABE5ED-FAB3-4174-A3F4-A9F2FDFF870B

Q34422206-72A53652-7802-47D3-9CBC-94D16EA59BD1

Q34422206-72E1A41B-286F-4144-BB0C-C504E40C83EE

Q34422206-754696CE-CB57-4084-9F99-74FE424AD86F

Q34422206-7927F24E-2D21-428B-A913-2C18CE50D683

P304

Q34422206-14A639C5-A721-4EFC-BC85-0AB57A1A120A

P31

Q34422206-E9E9B0D2-23BF-4711-AF8D-448E801AE71D

P356

Q34422206-37F96DF7-C53A-40E1-98CC-CB5F0A289C36

P407

Q34422206-C6863620-2271-4636-9B0B-110B19161E3A

P433

Q34422206-6D50808B-3C2D-4809-80AC-ED4A4BC05CF5

P478

Q34422206-AD4DFBE3-93CA-4B2B-A7B8-5A7EE9EBE401

P50

Q34422206-013ED0F4-1B91-49A1-B23B-7413307CE926

Q34422206-1E284250-5172-42B0-AE02-1FA048DE999E

Q34422206-63B48C3C-1FD2-4DE3-B148-D3E77A1E8B58

Q34422206-802C9509-E051-4FC2-B15C-F201DB2FBD47

Q34422206-8F0F7669-1007-49F8-8F47-3A375F5A38BA

Q34422206-D3B0DA11-1939-4702-B8D2-A6CC0902602A

P577

Q34422206-75BB6D36-F2ED-487C-8060-AB9E309D9729

P698

Q34422206-DD3C79E7-739E-404B-8877-F81295B73735

P921

Q34422206-76FECBC8-37B4-44CD-9A13-F8E8A30B9D86

P932

Q34422206-2DDB5E2A-DD4C-4DD0-B098-7FA7F869783F

P356

P1433

The New England Journal of Medicine

P1476

Enzalutamide in metastatic prostate cancer before chemotherapy.

@en

P2093

Andrew J Armstrong

http://www.w3.org/2001/XMLSchema#string

Bertrand Tombal

http://www.w3.org/2001/XMLSchema#string

Celestia S Higano

http://www.w3.org/2001/XMLSchema#string

Choung-Soo Kim

http://www.w3.org/2001/XMLSchema#string

Christopher P Evans

http://www.w3.org/2001/XMLSchema#string

Cora N Sternberg

http://www.w3.org/2001/XMLSchema#string

De Phung

http://www.w3.org/2001/XMLSchema#string

Frank Perabo

http://www.w3.org/2001/XMLSchema#string

Fred Saad

http://www.w3.org/2001/XMLSchema#string

Harry Mansbach

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Abiraterone in metastatic prostate cancer without previous chemotherapy

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Molecular determinants of resistance to antiandrogen therapy

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Alpha emitter radium-223 and survival in metastatic prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

P304

424-433

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1405095

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

371

http://www.w3.org/2001/XMLSchema#string

P50

Joan Carles Galcerán

Anthony M Joshua

Dana E Rathkopf

Mary-Ellen Taplin

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24881730

http://www.w3.org/2001/XMLSchema#string

P921

P932

4418931

http://www.w3.org/2001/XMLSchema#string